Last updated: August 6, 2025
Introduction
The Eurasian Patent Organization (EAPO) offers a crucial intellectual property (IP) regime for pharmaceuticals seeking patent protection across its member states, including Russia, Kazakhstan, Belarus, Armenia, and Kyrgyzstan. Patent EA201300235 exemplifies EAPO's approach to patenting drug innovations, offering insights into its claims scope and broader patent landscape. This analysis delves into the technical scope, specific claims, and strategic positioning of EA201300235 within the pharmaceutical patent landscape of the Eurasian region.
Patent Overview
EA201300235 was filed on March 25, 2013, and published on September 23, 2013. It claims a pharmaceutical composition designed to enhance drug stability and efficacy, particularly targeting antiviral or immunomodulatory agents. The patent's core innovation involves a specific combination of active ingredients formulated to improve bioavailability and reduce side effects, aligning with common trends in pharmaceutical innovation focused on combination therapies.
Scope of the Patent
Legal and Technical Scope
EA201300235’s scope encompasses:
- Pharmaceutical compositions comprising at least two active ingredients, explicitly aimed at antiviral or immunomodulatory applications.
- The specific ratios of these active ingredients that optimize stability and therapeutic efficacy.
- The methods of manufacturing such compositions, including the formulation process tailored to improve bioavailability.
- The use of the composition for treating specific viral infections, such as influenza, herpes, or hepatitis.
The patent’s scope extends to both composition claims (detailing the mixture and its proportions) and method claims (covering the therapeutic use), thereby providing comprehensive protection for both the product and its application.
Claims Composition
EA201300235 comprises multiple claims, categorized broadly into:
- Independent Claims: Defining the pharmaceutical composition with specific active ingredients and their ratios.
- Dependent Claims: Detailing particular embodiments, such as specific excipients, formulation techniques, or modes of administration.
The claims emphasize innovative combinations of known antiviral agents, with the inventive step rooted in optimizing their ratios and formulations—a common patent strategy to carve out novelty within the crowded pharmaceutical field.
Claim Specifics
- The primary independent claim appears to cover a pharmaceutical composition consisting of a first active agent (e.g., a nucleoside analogue) and a second active agent (e.g., an immunomodulator), with specified weight ratios.
- A key dependent claim likely specifies a specific formulation form (e.g., a tablet, capsule, or injectable) with detailed excipients.
- Additional claims address methods of manufacturing and methods of use, demonstrating an integrated patent scope covering both composition and application.
Patent Landscape Context
Regional and International Filing
EA201300235 is part of a broader patent landscape involving:
- Eurasian regional patents, offering single patent protection across member states.
- International filings under the Patent Cooperation Treaty (PCT), with counterparts potentially filed in the US, Europe, China, and other jurisdictions, reflecting the applicant’s global strategy.
- The patent is linked to prior art and concurrent patents, especially those covering antiviral compositions, emphasizing a crowded landscape with incremental innovations.
Competitive and Strategic Positioning
The patent’s positioning targets:
- Companies developing combination antiviral therapies.
- Firms seeking Eurasian market exclusivity to leverage the regional IP regime.
- Potential patent families with similar claims in other jurisdictions, informing the competitive landscape and patent strength.
Legal Status and Enforcement
As of the most recent updates, EA201300235 remains in force, with no recorded oppositions or litigations. Its enforceability is vital for market exclusivity and licensing opportunities across EAPO member states.
Implications for Patent Holders and Industry
EA201300235’s scope reflects a strategic approach by applicants seeking broad yet precise protection. Its combination-based claims align with pharmaceutical industry trends that favor patenting innovative drug combinations rather than mere formulations, thus creating a strong barrier to generic entry.
Operators must scrutinize the patent claims to avoid infringement and consider licensing deals, especially given the growing emphasis on antiviral formulations amid global health challenges. The patent landscape suggests ongoing innovation in combining existing antiviral agents with novel formulation strategies, emphasizing incremental but defensively strong patent protection.
Conclusion
Patent EA201300235 illustrates a focused protection strategy within Eurasia’s pharmaceutical patent landscape, primarily targeting combination antiviral compositions with detailed formulation claims. Its scope covers compositions, manufacturing methods, and therapeutic applications, positioning it as a robust barrier against generic competition within the EAPO member states.
Strategic insights include the importance of tailoring claims to balance broad coverage with enforceability, the value of global patent family expansion, and the need to monitor regional legal statuses for enforcement and licensing opportunities.
Key Takeaways
- Broad yet precise claims bolster patent strength, particularly in the crowded antiviral segment.
- Combination therapies remain a key patenting focus, aligning with global industry trends.
- Eurasian patent protections provide strategic regional exclusivity, especially valuable for markets with limited local IP regimes.
- Maintaining legal compliance and monitoring opposition or litigation are critical for patent enforceability.
- Patent families extending beyond Eurasia can maximize global market leverage.
FAQs
-
What is the primary innovation claimed by EA201300235?
The patent claims a pharmaceutical composition combining specific active ingredients, optimized for antiviral effectiveness and improved bioavailability, with detailed ratios and formulation processes.
-
Can EA201300235 be enforced outside Eurasia?
Not directly. Enforcement is limited to EAPO member states. To extend protection, the patent holder would need to file corresponding applications in other jurisdictions or for patent family rights.
-
How does the patent landscape influence drug development strategies in Eurasia?
It incentivizes incremental innovation—such as optimized combinations or formulations—and highlights the importance of protecting therapeutic claims to secure regional market exclusivity.
-
Are there any challenges associated with patenting combination therapies in Eurasia?
Yes, requirements for demonstrating inventive step can be complex, especially when combining known agents. Clear, non-obvious modifications or synergistic advantages are vital.
-
What should patent applicants consider when filing in Eurasia?
They should tailor claims to regional patent requirements, consider filing international patent applications for broader coverage, and monitor existing patents for potential overlaps or infringing claims.
Sources
[1] Eurasian Patent Office Database, Patent EA201300235
[2] Eurasian Patent Convention, Official Documentation
[3] GLOBAL Patent Landscape Reports, 2022
[4] Industry-specific patent filing trends, WIPO Patent Reports
